technical information for policy-makers and health professionals.
Available at: http://www.who.int/reproductive-
(6) Schuind A. HPV-007 Final Analysis. Presented at: SGO's Annual Meeting
on Women's Cancer. March 10, 2008
(7) Dessy F, David MP, Schuind A et al. Evaluation of HPV neutralizing
antibodies from an extended follow up study through 5.5 years in women
vaccinated with GSKs prophylactic Cervical Cancer Candidate Vaccine.
Presented at IPC 2007
(8) Deschamps D, Hardt K, Spiessens B et al. Safety of human
papillomavirus (Hpv)-16/18 AS04 adjuvanted vaccine for cervical cancer
prevention: integrated summary of 11 clinical trials. Presented at
(9) Harper DM, Franco EL, Wheeler C, Ferris DG, et al. Efficacy of a
bivalent L1 virus-like particle vaccine in prevention of infection
with human papillomavirus types 16 and 18 in young women: a randomised
controlled trial. Lancet 2004;364:1757-65.
(10) Harper DM, Franco EL et al. Sustained efficacy up to 4.5 years of a
bivalent L1 virus-like particle vaccine against human papillomavirus
types 16 and 18: follow-up from randomised control trial. The Lancet
2006; 367: 1247-1255.
(11) Gall, S., et al. Sustained Efficacy up to 5.5 years in women
vaccinated with an AS04 Adjuvanted HPV 16/18 L1 VLP Vaccine. Presented
at AACR Medical Meeting. April 17, 2007.
(12) Harper DM, Gall S, et al. HPV-007 Efficacy Abstract. "Sustained
Immunogenicity and high efficacy against HPV-16/18 related cervical
neoplasia: Long-term follow-up through 6.4 years in women vaccinated
with CERVARIX (GSKS HPV 16/18 AS04 Ca
Copyright©2008 PR Newswire.
All rights reserved